SHORT COMMUNICATION

Use of an Artificial Neural Network to Identify Patient Clusters in a Large Cohort of Patients with Melanoma by Simultaneous Analysis of Costs and Clinical Characteristics

Giovanni DAMIANI1,2, Alessandra BUJA*, Enzo GROSSI3, Michele RIVERA1, Anna DE POLO4, Giuseppe DE LUCA4, Manuel ZORZI6, Antonella VECCHIATO7, Paolo DEL FIORE8, Mario SAIA9, Vincenzo BALDO4, Massimo RUGGE6, Carlo Riccardo ROSSI1 and Gianfranco DAMIANI1,10

1Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, 2Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, 3PhD Degree Program in Pharmaco logical Sciences, Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, 4Department of Cardiological, Vascular, and Thoracic Sciences, and Public Health, University of Padua, Via Loredan 18, 17-35128 Padova, 5Villa Santa Maria Institute, Neuropsychiatric Rehabilitation Center, Tavernierio (Como), 6Veneto Tumor Registry, Azienda Zero, 7Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 8Veneto Regional Authority, Padua, 9Fondazione Poli clinico Universitario A. Gemelli IRCCS, Rome, and 10Università Cattolica del Sacro Cuore, Rome, Italy. *E-mail: alessandra.buja@unipd.it

Accepted Oct 28, 2020; Epub ahead of print Nov 2, 2020

The incidence of cutaneous malignant melanoma (CMM) in Italy has increased in the last decade, leading to public health concern and rising costs of healthcare (1, 2). In addition to individual susceptibility to development of CMM, several environmental variables influence prognosis in this disease. These variables include social disparities, socioeconomic status, education and marital status (3). However, the impact of these variables on costs is unknown. The current study used a new methodology, based on an artificial neural network (ANN), to decodify this complexity by simultaneously describing the relationships between clinical, sociodemographic, outcome, and cost variables, and grouping patients into clusters (4, 5).

MATERIALS, METHODS AND RESULTS

This study evaluated a collaborative registry of 556 patients (Veneto Tumor Registry & Veneto Oncology Network)1, who were diagnosed with CMM by a board certified dermatopathologist in 2015 in 4 of the 7 provinces of the Veneto Region in Northern Italy (3). For each patient, the CMM registry includes a set of tumour characteristics, including: tumour-node-metastasis (TNM) stage at diagnosis; Breslow thickness (mm); Clark’s level of invasion (I–V); presence of ulceration (yes/no); site (trunk, head, limbs); cost categories tertiles (scintigraphic, surgical, medical, instrumental, cyto/histological, microbiological, blood examinations, radiotherapeutic, radiological and total (costs based on “Hospital Discharge Forms (SDO)”) CMM-specific mortality.

Costs were assessed from the perspective of the Italian National Health System (Italian NHS), taking only direct costs into account. Patients were linked via unique anonymous identification codes to all administrative data regarding their hospital admissions, day hospital service use, drug usage, visits to emergency services, medical devices used at home, and hospice admissions. These data were used to compute the direct costs for each patient in the 5 years after diagnoses of their CMM.

Descriptive analyses were performed using absolute and relative frequencies for categorical variables. A semantic connectivity map was constructed using Auto Contractive Map (AutoCM, Senseon1), Rome, Italy) to elucidate variable links (4). The system highlights the natural links on a graph based and distances between variables reflect the weights of the ANN (Appendix S17). AutoCM has many relevant features: (i) non-linear associations among variables are preserved; (ii) patterns of connections between clusters of variables are captured; and (iii) complex similarities among variables emerge.

Clinical/histological and demographic data for the 556 included CMM are summarized in Table S1. The AutoCM results are shown in Fig. 1. The item “1–6 mitoses” is the centre (main attractor) of our unsupervised analysis, demonstrating its clustering value vis-à-vis the spread of its 4 main branches (strength > 0.60) depicting 4 endotypes. The use of radiotherapy, education and marital status were central descriptors in our database. The 1st endotype grouped together (or “clusters”) those patients with advance-stage CMM who had nodular and ulcerated CMM, a high risk of death, and a heavy economic burden. The 2nd endotype clustered patients > 60 years of age who had CMM on the trunk or face, and high procedural and therapeutic costs. The 3rd endotype clustered patients with stage Ib CMM. The 4th endotype clustered patients with no radiotherapy costs, comprising 4 main subsets, each with their own biological and socioeconomic variable items. Further details of the items interactions are shown in Appendix S2.

Our results, in-line with the idea of precision medicine, also suggest a potential endotype-guided treatment Appendix S3 that may implement CMM follow-up visits.

DISCUSSION

Through a combined analysis of the clinical, sociodemographic and economic variables associated with CMM, using an ANN, endotypes were identified that can be used to estimate an individual patient’s final costs based on their baseline characteristics. Based on these patient clusters, further tests can be suggested to add to the routine tests used for patients with CMM at each TNM stage.

Use of a machine learning approach such as this can generate a comprehensive model that establishes complex links between clinical, sociodemographic, outcome, and cost variables. Machine learning has also been used by Finlayson et al. (6) on a small database containing the clinical, therapeutic and molecular features of 237 cases of advanced CMM, with the aim of helping clinicians predict patients survival and make therapeutic decisions. In our database the main variable, also regarded as the “attractor”, was “1–6 mitoses. Mitotic index is not included in the 8th edition of the American Joint Committee on Cancer TNM system, suggesting that it is optional to report this variable for prognostic purposes. The value of the mitotic index as a prognostic indicator in CMM has been debated, partly because of its moderate interobserver
variability (7). The findings of the current study suggest that the mitotic index is relevant for predicting the costs of CMM from baseline information.

The semantic map used in the current study revealed 4 endotypes, through using the database as “learning material” for the evolutive algorithm of the ANN (8). The internal validity of the algorithm is high and measurable; however, further study is required to determine its external validity, since the ANN was designed to find connections among variables in the database in the current study. Evidence to support external validity come from the literature, specifically regarding marital status and education. In line with literature (3), we confirmed that marital status represents a valuable information to be recorded in CMM patients. An association between married status and lower costs may stem from the presence of a partner resulting in earlier diagnosis of a skin cancer. This suggests that patients with little or no formal education are less inclined to access healthcare services (3).

This study has some limitations. Data regarding the patients’ self-reported educational level may not be reliable, although a previous Italian study on the validity of data on education levels recorded in hospital discharge records found that it was in the good-to-excellent range (9). The current study lacks information on patients’ lifestyles and other socioeconomic parameters that might reduce the influence of educational level on the natural history of their CMM.

In conclusion, in CMM, clinical variables together with costs were indispensable to cluster patients in endotypes by ANN. Endotypes-guided management is affirming as new promising strategy to guide medical and surgical therapies (10, 11).

ACKNOWLEDGEMENTS

IRB approval. Veneto Oncological Institute Ethics Committee (n° 695/20.10.2016).
The authors have no conflicts of interest to declare.

REFERENCES


